Cardiology

PCSK9 inhibitors reduce lipoprotein (a) production

A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

Diabetes

Low HDL-C, high TG increase risk for diabetic kidney disease

(HealthDay)—For patients with diabetes, low high-density lipoprotein cholesterol (HDL-C) and high triglyceride (TG) levels are associated with increased risk of diabetic kidney disease (defined as low estimated glomerular ...

Diabetes

Evolocumab safe, effective for those with dysglycemia, MetS

(HealthDay)—For patients with or without dysglycemia or metabolic syndrome (MetS), evolocumab is safe and efficacious for reducing low-density lipoprotein cholesterol at 52 weeks, according to research published online ...

Cardiology

Alirocumab cuts apheresis rates in familial hypercholesterolemia

Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce ...

Diabetes

Quality improvement strategy ups achievement of T2DM goals

(HealthDay)—A multicomponent quality improvement (QI) strategy can improve achievement of diabetes care goals in a population of type 2 diabetes patients with poor cardiometabolic profiles, according to a study published ...

page 13 from 22